Abstract
While immune checkpoint inhibitors (ICI) have revolutionized treatment of metastatic melanoma (MM) patients, still 40–60% of patients do not achieve a clinical benefit. Tissue-based predictive biomarkers are not validated in MM, and non-invasive liquid biomarkers can be an alternative source. Whole-blood transcriptome has shown to identify early response to ICI in urothelial cancer, thus have a potential in the context of MM.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
